Global healthcare company, Abbott announced that its continuous glucose monitoring system, Lingo, is now available without a prescription in the United States.
Words of unknown meaning Includes a biosensor and mobile app based on Abbott’s FreeStyle Libre continuous glucose monitoring technology.
The system is a biometric wearable device designed for people over 18 years of age who do not take insulin.
The product aims to track glucose in real time and provide end users with personalized insights and coaching to build healthy habits, re-educate their metabolism, and improve overall health.
“There is tremendous interest in tracking biomarkers using consumer-delivered trackers to provide previously undetectable insights into health and wellness,” Olivier Lopas, vice president of Abbott’s Lingo business, said in a statement.
“Glucose is a powerful signal that reflects your body’s unique response to food and lifestyle. Abbott’s Lingo tracks glucose 24/7, turning data into insights and bridging the gap between traditional health management and preventative care. Lingo empowers individuals to create new healthy habits and take control of their health and wellness.”
The bigger trend
August, Abbott We have launched the Vertigo Coach app in India, where nearly 10 million people suffer from the condition. The product is available for both Android and iOS devices, and the mobile app provides information and resources to help people with vertigo manage their condition.
In 2022, ABbott’s implantable cardiac sensor system, CardioMEMS, has received expanded FDA approval, making the technology available to patients with early-stage heart failure.
Designed to monitor pressure changes in the heart, the system is implanted into a patient’s pulmonary artery through a minimally invasive procedure.
In 2021, Abbott The FDA has cleared imaging software that uses artificial intelligence to help doctors see blood flow and blockages in heart blood vessels more clearly.
Ultreon 1.0 software combines optical coherence tomography and AI to help physicians make decisions about next steps in treatment.
Other players in the glucose monitoring space include: Dexcom’s Stelo is a wearable glucose monitor that was released in the U.S. market in August. It tracks glucose 24 hours a day and does not require a prescription.
Medtronic offers two smart continuous glucose monitoring systems: Guardian Connect alerts patients up to 60 minutes in advance of high or low blood sugar levels, allowing them to take action; Guardian Sensor 3 can predict high or low blood sugar levels up to an hour in advance and is integrated with the company’s latest insulin pump therapy technology.
The HIMSS Healthcare Cybersecurity Forum will be held in Washington, DC from October 31 to November 1. Learn more and register.
